Literature DB >> 27668062

Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2016        PMID： 27668062      PMCID： PMC5013846     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  6 in total

1.  Executive summary: Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

2.  Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Authors:  Alan J Garber; Allen B King; Stefano Del Prato; Seamus Sreenan; Mustafa K Balci; Manuel Muñoz-Torres; Julio Rosenstock; Lars A Endahl; Ann Marie Ocampo Francisco; Priscilla Hollander
Journal:  Lancet       Date:  2012-04-21       Impact factor: 79.321

3.  Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.

Authors:  Gregory R Fulcher; Jens Sandahl Christiansen; Ganapathi Bantwal; Miroslawa Polaszewska-Muszynska; Henriette Mersebach; Thomas H Andersen; Leo K Niskanen
Journal:  Diabetes Care       Date:  2014-05-08       Impact factor: 19.112

4.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

5.  Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

Authors:  Bernard Zinman; J Hans DeVries; Bruce Bode; David Russell-Jones; Lawrence A Leiter; Alan Moses; Thue Johansen; Robert Ratner
Journal:  Lancet Diabetes Endocrinol       Date:  2013-07-09       Impact factor: 32.069

6.  Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.

Authors:  M J Davies; J L Gross; Y Ono; T Sasaki; G Bantwal; M A Gall; M Niemeyer; H Seino
Journal:  Diabetes Obes Metab       Date:  2014-05-08       Impact factor: 6.577
  6 in total
  2 in total

Review 1.  Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons.

Authors:  Naeema Hanif; Hezhou Wu; Peizhou Xu; Yun Li; Amir Bibi; Asma Zulfiqar; Muhammad Zafar Iqbal; Muhammad Tahir; Xiangyang Zhang; Asif Ali
Journal:  Curr Issues Mol Biol       Date:  2022-02-11       Impact factor: 2.976

2.  Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population.

Authors:  Inderpal Singh Kochar; Aashish Sethi
Journal:  Int J Pediatr Endocrinol       Date:  2018-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.